The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- Vaccine, gene therapy makers fall after Peter Marks resignation
- CRISPR Therapeutics COO Julianne Bruno Resigns